Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.48 |
| ▸ | CDK2 | P24941 | 8/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.48 |
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26379077 | 0.88 | CDK1 (0.46) | CDK1CDK2KDRIGF1RPTK2 | |
| SCHEMBL26379095 | 0.87 | ALK (0.58) | CDK1CDK2KDREGFRALK | |
| SCHEMBL26379025 | 0.86 | EGFR (0.51) | CDK1CDK2KDRIGF1RPTK2 | |
| SCHEMBL26378981 | 0.85 | EGFR (0.63) | IGF1RPTK2EGFRALK | |
| SCHEMBL26379018 | 0.85 | CDK1 (0.47) | CDK1CDK2KDRIGF1RPTK2 | |
| SCHEMBL26380082 | 0.84 | ALK (0.45) | CDK1CDK2KDREGFRALK | |
| SCHEMBL26380087 | 0.84 | ALK (0.45) | CDK1CDK2KDRPTK2EGFR | |
| SCHEMBL26379116 | 0.84 | CDK7 (0.47) | CDK1CDK2KDRPTK2EGFR | |
| SCHEMBL26379105 | 0.83 | EGFR (0.38) | CDK1CDK2KDRPTK2EGFR | |
| SCHEMBL26379110 | 0.83 | EGFR (0.44) | CDK1CDK2KDRIGF1RPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2021238827-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | 南京红云生物科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | CDK1 130/4885CDK2 96/4885KDR 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.